PD-L1 ( CD274 ) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PD-L1
(
CD274
) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma
Authors
Keywords
-
Journal
OncoImmunology
Volume 12, Issue 1, Pages -
Publisher
Informa UK Limited
Online
2023-10-19
DOI
10.1080/2162402x.2023.2267744
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Accelerating cancer omics and precision oncology in health care and research: a Lancet Oncology Commission
- (2023) Raffaella Casolino et al. LANCET ONCOLOGY
- Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt).
- (2023) Yohann Loriot et al. JOURNAL OF CLINICAL ONCOLOGY
- Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials
- (2022) Joaquim Bellmunt et al. CLINICAL CANCER RESEARCH
- Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint Inhibition
- (2022) Franziska Erlmeier et al. EUROPEAN UROLOGY
- Bladder tumor subtype commitment occurs in carcinoma in-situ driven by key signaling pathways including ECM remodeling
- (2021) Adrian Wullweber et al. CANCER RESEARCH
- PD-L1 as a biomarker of response to immune-checkpoint inhibitors
- (2021) Deborah Blythe Doroshow et al. Nature Reviews Clinical Oncology
- Pan-cancer landscape of CD274 (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression
- (2021) Richard S.P. Huang et al. Journal for ImmunoTherapy of Cancer
- Molecular and Immune Correlates of PDCD1 (PD-1), PD-L1 (CD274), and PD-L2 (PDCD1LG2) DNA Methylation in Triple Negative Breast Cancer
- (2021) Damian J. Ralser et al. JOURNAL OF IMMUNOTHERAPY
- Utility of stromal tumor infiltrating lymphocyte scoring (sTILs) for risk stratification of patients with muscle-invasive urothelial bladder cancer after radical cystectomy
- (2021) Danijel Sikic et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy
- (2021) Karl H. Tully et al. UROLOGY
- Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort
- (2021) Veronika Weyerer et al. WORLD JOURNAL OF UROLOGY
- Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance
- (2021) Felicity Newell et al. CANCER CELL
- The landscape of CD28, CD80, CD86, CTLA4, and ICOS DNA methylation in head and neck squamous cell carcinomas
- (2020) Luka de Vos et al. Epigenetics
- Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy
- (2020) Markus Eckstein et al. Journal for ImmunoTherapy of Cancer
- CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)
- (2020) Simon Fietz et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The Tumor Immune Microenvironment Drives a Prognostic Relevance that Correlates with Bladder Cancer Subtypes
- (2019) Carolin Pfannstiel et al. Cancer Immunology Research
- New insights in predictive determinants of the tumor immune microenvironment for immune checkpoint inhibition: a never ending story?
- (2019) Markus Eckstein et al. Annals of Translational Medicine
- A Consensus Molecular Classification of Muscle-invasive Bladder Cancer
- (2019) Aurélie Kamoun et al. EUROPEAN UROLOGY
- Evolution of PD-1 and PD-L1 Gene and Protein Expression in Primary Tumors and Corresponding Liver Metastases of Metastatic Bladder Cancer
- (2018) Markus Eckstein et al. EUROPEAN UROLOGY
- Epigenome-wide analysis reveals specific DNA hypermethylation of T cells during human hematopoietic differentiation
- (2018) J Ramón Tejedor et al. Epigenomics
- Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab
- (2018) Markus Eckstein et al. EUROPEAN JOURNAL OF CANCER
- PD-L1 methylation regulates PD-L1 expression and is associated with melanoma survival
- (2018) Goran Micevic et al. Pigment Cell & Melanoma Research
- PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies
- (2017) Barbara Uhl et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
- (2017) Arjun V Balar et al. LANCET ONCOLOGY
- PD-L1 (CD274) and PD-L2 (PDCD1LG2) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas
- (2017) Alina Franzen et al. Oncotarget
- Epigenomic Profiling of Human CD4 + T Cells Supports a Linear Differentiation Model and Highlights Molecular Regulators of Memory Development
- (2016) Pawel Durek et al. IMMUNITY
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- PD-L1 (CD274) promoter methylation predicts survival in patients with acute myeloid leukemia
- (2016) D Goltz et al. LEUKEMIA
- The epigenetic landscape of T cell exhaustion
- (2016) D. R. Sen et al. SCIENCE
- Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade
- (2016) K. E. Pauken et al. SCIENCE
- PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy
- (2016) Heidrun Gevensleben et al. Oncotarget
- PD-L1 (CD274) promoter methylation predicts survival in colorectal cancer patients
- (2016) Diane Goltz et al. OncoImmunology
- Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use
- (2016) Vipulkumar Dadhania et al. EBioMedicine
- Coordinated Changes in DNA Methylation in Antigen-Specific Memory CD4 T Cells
- (2013) S.-i. Hashimoto et al. JOURNAL OF IMMUNOLOGY
- Analysis of DNA Methylation of Multiple Genes in Microdissected Cells From Formalin-fixed and Paraffin-embedded Tissues
- (2009) Dimo Dietrich et al. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started